Every 424B that Xenon Pharmaceuticals Inc (XENE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow XENE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XENE filings page.
Xenon Pharmaceuticals is offering 10,526,317 common shares and, in lieu of shares to certain investors, 877,194 pre-funded warrants via a prospectus supplement under its shelf registration. The offering price is $57.00 per common share (pre-funded warrant price $56.9999), with estimated net proceeds to the company of approximately $615.3 million and a possible additional 1,710,526 share option for the underwriters.
The prospectus supplement notes the pre-funded warrants have an exercise price of $0.0001, will not be listed, and holders will have limited liquidity until exercise. Shares outstanding used for dilution calculations were 80,010,790 common shares as of December 31, 2025. The underwriters expect delivery on or about March 12, 2026.
Xenon Pharmaceuticals Inc. is offering $500.0 million of its common shares pursuant to a preliminary prospectus supplement. The underwriters have a 30-day option to purchase an additional $75.0 million of common shares. The company’s common shares trade on Nasdaq under the symbol XENE, with the last reported sale price of $41.94 on March 6, 2026. The prospectus supplement states 80,010,790 common shares outstanding as of December 31, 2025, and assumes no exercise of the underwriters’ option for outstanding-share calculations. The filing also discloses positive Phase 3 topline results for azetukalner in focal onset seizures and a planned NDA submission in Q3 2026 for that indication.
Xenon Pharmaceuticals Inc. is filing a prospectus supplement to offer up to $400,000,000 of common shares through an at-the-market equity program with Jefferies LLC and Stifel, Nicolaus & Company as sales agents.
The prospectus supplement replaces a prior prospectus and states that $291,084,564 of Shares have previously been sold under the Sales Agreement. The offering contemplates sales on the Nasdaq Global Market at prices that will vary; the supplement cites a last reported sale price of $44.92 per share on February 26, 2026. The disclosure notes estimated underwriting commissions up to 3.0%, customary indemnities to agents, intended uses of proceeds to fund clinical development and corporate purposes, and that there is no escrow arrangement. Shares outstanding were 80,010,790 as of December 31, 2025.